Citadel Advisors’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Citadel Advisors’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-216,165	Closed	-$42.2K	–	15746
2023 Q4	$42.2K	Buy	216,165 +189,999	+726%	+$41.3K	﹤0.01%	11967
2023 Q3	$10.1K	Buy	+26,166	New	+$17.7K	﹤0.01%	13088
2022 Q2	–	Sell	-10,535	Closed	-$17.6K	–	14456
2022 Q1	$21K	Sell	10,535 -2,178	-17%	-$7.53K	﹤0.01%	13230
2021 Q4	$59K	Buy	+12,713	New	+$104K	﹤0.01%	13158

Other funds holding BTTX

CIAS

Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Citadel Advisors's BTTX Position: Q1 2024 in Review

Citadel Advisors sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 216,165 shares — an estimated $42.2K sold.

Citadel Advisors first reported a position in BTTX in Q4 2021 and held it in 4 quarters. The position peaked at $59K in Q4 2021. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

Citadel Advisors reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 216,165 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $42.2K.
Citadel Advisors first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Citadel Advisors's Better Therapeutics, Inc. Common Stock position peaked at $59K in Q4 2021.
3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.